期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向肿瘤坏死因子的炎性肠病治疗研究进展 被引量：4

下载PDF
导出
摘要 肿瘤坏死因子在介导炎性肠病(IBD),特别是在克罗恩病的炎症过程中发挥着重要作用。现在已有多种以肿瘤坏死因子为靶点的药物用于临床或正在进行临床研究。
作者 肖瑛 许元富 周圆 杨纯正
机构地区 中国医学科学院血液学研究所实验血液学国家重点实验室
出处 《世界临床药物》 CAS 2004年第11期683-687,共5页 World Clinical Drug
关键词 肿瘤坏死因子 炎性肠病 治疗 靶向 靶点 研究进展 克罗恩病 过程 重要作用
分类号 R574 [医药卫生—消化系统] R730 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Vasiliauskas EA,Kam LY,Abreu-Martin MT,et al.An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease[].Gastroenterology.1999
  • 2Papadakis KT,Targan SR.Tumor necrosis factor: biology and therapeutic inhibitors[].Gastroenterology.2000
  • 3Sandborn WJ,Hanauer SB.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety[].Inflammatory Bowel Diseases.1999
  • 4Schreiber S,Rutgeerts P,Fedorak R,et al.CDP870,a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn’s disease(CD)[].Gastroenterology.2003
  • 5Sandborn WJ,Hanauer SB,Katz S.Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial[].Gastroenterology.2001
  • 6D’Haens G,Swijsen C,Noman M,et al.Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial[].The American journal of Gastroenterology.2001
  • 7Hommes D,van den Blink B,Plasse T,ef al.Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease[].Gastroenterology.2002
  • 8Murch SH,Braegger CP,Walker-Smith JA,et al.Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory boweldisease[].Gut.1993
  • 9Rutgeerts P,Lemmens L,van Assche G,ef al.Recombinant soluble p55 receptor induces remission, is non-immunogenic and well tolerated in active Crohn’s disease: results of a randomized pilot trial[].Gastroenterology.2001
  • 10Salituro FG,Germann UA,Wilson KP,ef al.Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases[].Current Medical Chemistry.1999

同被引文献24

  • 1曹元华.日本新修订的白塞综合征诊断与分期及临床严重度标准[J].国际皮肤性病学杂志,2006,32(1):57-58. 被引量：12
  • 2欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495. 被引量：751
  • 3Wettstem AR, Meagher AP. Thalidomide in Crohn's disease [J]. Lancet ,1997,350(9089):1445.
  • 4Lienenluke B, Stojanovic T, Fiebig T, et al . Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the ret-role of endothelial cell-leukocyte interaction [J]. Br J Pharmacol , 2001,133(8):1414.
  • 5Bariol C , Meagher AP, Vickers CR, et al . Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease[J]. J Gastroenterol Hepatol ,2002,17 (2) : 135.
  • 6Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease [ J]. Gastroenterology, 2004, 126 : 1593-1610.
  • 7Murch SH, Braegger Location of turnout CP, Walker-Smith necrosis factor immunohistochemistry in disease [J]. Gut, 1993, JA, et al. alpha by chronic inflammatory bowel 34 : 1705-1709.
  • 8Hanauer SB, Feagan BG, Lichtenstein GR, et aL Maintenance infliximab for Crohn' s disease: the ACCENT I randomised trial [ J]. Lancet, 2002, 359:1541-1549.
  • 9Direskeneli H, Ergun T, Yavuz S, et al. Thalidomide has both anti-inflammatory and regulatory effects in Behcet' s disease [ J ]. Clin Rheumatol, 2008, 27:373- 375.
  • 10van de Donk NW, KrSger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma [J]. Blood, 2006, 107:3415-3416.

引证文献4

二级引证文献14

世界临床药物
2004年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部